Relevance of HTLV-1 proviral load in asymptomatic and symptomatic patients living in endemic and non-endemic areas of Argentina


Autoři: María Verónica Pineda aff001;  María Belén Bouzas aff002;  Mirta Remesar aff004;  Ariel Fridman aff005;  Carlos Remondegui aff006;  Lilia Mammana aff002;  Natalia Altamirano aff001;  Patricia Paradiso aff007;  Patricia Costantini aff008;  Luciana Tadey aff002;  Paula Aulicino aff001;  Andrea Mangano aff001
Působiště autorů: Laboratorio de Biología Celular y Retrovirus-CONICET, Unidad de Virología y Epidemiología Molecular, Hospital de Pediatría "Prof. Dr. Juan P. Garrahan", Ciudad Autónoma de Buenos Aires, Argentina aff001;  Unidad de Virología, Hospital de Infecciosas “Francisco J. Muñiz”, Ciudad Autónoma de Buenos Aires, Argentina aff002;  División de Análisis Clínicos, Hospital de Infecciosas “Francisco J. Muñiz”, Ciudad Autónoma de Buenos Aires, Argentina aff003;  Centro Regional de Hemoterapia Garrahan, Hospital de Pediatría "Prof. Dr. Juan P. Garrahan", Ciudad Autónoma de Buenos Aires, Argentina aff004;  Laboratorio Central de Jujuy, Jujuy, Argentina aff005;  Servicio de Infectología y Enfermedades Tropicales, Hospital San Roque, Jujuy, Argentina aff006;  Servicio de Hemoterapia, Hospital Durand, Ciudad Autónoma de Buenos Aires, Argentina aff007;  Instituto de Oncología Ángel H. Roffo, Ciudad Autónoma de Buenos Aires, Argentina aff008
Vyšlo v časopise: PLoS ONE 14(11)
Kategorie: Research Article
doi: 10.1371/journal.pone.0225596

Souhrn

HTLV-1 proviral load (pVL) in peripheral blood mononuclear cell (PBMCs) is proposed as a marker of disease progression but its role still remains controversial. The aim of this study was to evaluate the levels of HTLV-1 pVL in symptomatic patients and asymptomatic HTLV-1 carriers. In this cross-sectional study the pVL was measured by Real Time PCR in 102 asymptomatic carriers and 22 symptomatic patients (5ATLL, 15 TSP and 2 uveitis). We observed that the HTLV-1 pVL was significantly higher in symptomatic patients (median = 4.99 log10 HTLV-1 copies /106 PBMCs) compared to asymptomatic HTLV-1 carriers (median = 4.38 log10 HTLV-1 copies /106 PBMCs; p = 0.0030). A wide variation on the HTLV-1 pVL levels among asymptomatic HTLV-1 carriers was observed with some pVL as high as those observed in symptomatic patients. The asymptomatic HTLV-1 carriers were divided according to the place of birth and the highest levels of pVL were detected among patients from endemics areas from the North of Argentina. Our results reinforce the usefulness of the proviral load would be a prognostic marker of HTLV-1 disease progression. Moreover, host, viral or socio-environmental factors cannot be excluded as determinant of high proviral load.

Klíčová slova:

Argentina – Blood donors – HTLV-1 – Pathogenesis – Peru – Uveitis – Bolivia – Paraguay


Zdroje

1. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci. 1980;77 (12): 7415–7419. doi: 10.1073/pnas.77.12.7415 6261256

2. Hinuma Y, Nagata K, Hanaoka M, Nakai M, Matsumoto T, Kinoshita KI, et al. Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci U S A. 1981;78: 6476–6480. doi: 10.1073/pnas.78.10.6476 7031654

3. Gessain A, Vernant JC, Maurs L, Barin F, Gout O, Calender A, et al. Antibodies To Human T-Lymphotropic Virus Type-I in Patients With Tropical Spastic Paraparesis. Lancet. 1985;326: 407–410. doi: 10.1016/S0140-6736(85)92734-5

4. Osame M, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A, Matsumoto M and TM. HTLV-1 associated myelopathy, a new clinical entity. Lancet. 1986;1: 1031–1032. doi: 10.1016/S0140-6736(86)91298-5

5. Mochizuki M, Watanabe T, Yamaguchi K, Takatsuki K, Yoshimura K, Shirao M, et al. HTLV‐I Uveitis: A Distinct Clinical Entity Caused by HTLV‐I. Jpn J Cancer Res. 1992;83: 236–239. doi: 10.1111/j.1349-7006.1992.tb00092.x 1582883

6. Nishioka K, Maruyama I, Sato K, Kitajima I, Nakajima Y, Osame M. Chronic Inflammatory Arthropathy Associated With HTLV-I. Lancet. 1989;1 (8635): 441. doi: 10.1016/S0140-6736(89)90038-X

7. Yamaguchi K, Watanabe T. Human T lymphotropic virus type-I and adult T-cell leukemia in Japan. Int J Hematol. 2002;76 (2)kkk: 240–245.

8. Iwanaga M, Watanabe T, Utsunomiya A, Okayama A, Uchimaru K, Koh KR, et al. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: A nationwide prospective study in Japan. Blood. 2010;116: 1211–1219. doi: 10.1182/blood-2009-12-257410 20448111

9. Kaplan JE, Osame M, Kubota H, Igata A, Nishitani H, Maeda Y, Khabbaz RF JR. The risk of development of HTLV-I associated myelopathy/tropical spactic paraparesis among persons infected with HTLV-1. J Acquir Immune Defic Syndr. 1990;3 (11): 1096–1101. 2213510

10. Maloney EM, Cleghorn FR, Morgan OS, Rodgers-Johnson P, Cranston B, Jack N, Blattner WA, Bartholomew C and MA. Incidence of HTLV-1-associated myelopathy/ tropical spastic paraparesis (HAM/TSP) in Jamaica and Trinidad. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17 (2): 167–170. doi: 10.1097/00042560-199802010-00011 9473019

11. Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol. 2012;3: 1–23. doi: 10.3389/fmicb.2012.00001

12. Gotuzzo E. Risk of transfusion-transmitted human T-cell lymphotropic virus-type I in Latin America. Int J Infect Dis. 2000;4(2): 59–61. doi: 10.1016/s1201-9712(00)90094-8 10737839

13. Gastaldello R, Hall WW, Gallego S. Seroepidemiology of HTLV-I / II in Argentina: An Overview. 2004;35 (3): 301–308.

14. Bouzas MB, Muchinik GR, Zapiola I, De Rosa MF, Perez Bianco R, Pimentel E, Dengra C, Del Pino N, Gallo D HC. Prevalence of HTLV-I/II among blood bank donors in Argentina. J Acquir Immune Defic Syndr. 1992;5(12): 1275–1276. doi: 10.1097/00126334-199212000-00014 1453338

15. Blejer JL1, Saguier MC, Salamone HJ CL. Determination of anti-HTLV-I/II antibodies: Experience in 28,897 blood donations in Buenos Aires. Sangre (Barc). 1995;40(6): 447–451.

16. Richardson JH, Edwards AJ, Cruickshank JK, Rudge P, Dalgleish AG. In vivo cellular tropism of human T-cell leukemia virus type 1. J Virol. 1990;64: 5682–5687. 1976827

17. Gillet NA, Malani N, Melamed A, Gormley N, Carter R, Bentley D, Berry C, Bushman FD, Taylor GP and BC. The host genomic environment of the provirus deter- mines the abundance of HTLV-1-infected T-cell clones. Blood. 2011;117: 3113–3122. doi: 10.1182/blood-2010-10-312926 21228324

18. Wattel E, Vartanian JP, Pannetier C, Wain-Hobson S. Clonal expansion of human T-cell leukemia virus type I-infected cells in asymptomatic and symptomatic carriers without malignancy. J Virol. 1995;69: 2863–2868. 7707509

19. Okayama A, Stuver S, Matsuoka M, Ishizaki J, Tanaka GI, Kubuki Y, et al. Role of HTLV-1 proviral DNA load and clonality in the development of adult T-cell leukemia/lymphoma in asymptomatic carriers. Int J Cancer. 2004;110: 621–625. doi: 10.1002/ijc.20144 15122598

20. Manns A, Miley WJ, Wilks RJ, Morgan OS, Hanchard B, Wharfe G, et al. Quantitative proviral DNA and antibody levels in the natural history of HTLV-I infection. J Infect Dis. 1999;180 (5): 1487–1493. Available: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med4&AN=10515807%5Cnhttp://sfx.scholarsportal.info/uhn?sid=OVID:medline&id=pmid:10515807&id=doi:&issn=0022-1899&isbn=&volume=180&issue=5&spage=1487&pages=1487-93&date=1999&title=Journal+ doi: 10.1086/315088 10515807

21. Demontis MA, Hilburn S, Taylor GP. Human T Cell Lymphotropic Virus Type 1 Viral Load Variability and Long-Term Trends in Asymptomatic Carriers and in Patients with Human T Cell Lymphotropic Virus Type 1-Related Diseases. AIDS Res Hum Retroviruses. 2013;29 (2): 359–364. doi: 10.1089/AID.2012.0132 22894552

22. Taylor GP, Tosswill JH, Matutes E, Daenke S, Hall S, Bain BJ, Davis R, Thomas D, Rossor M, Bangham CR and WJ. Prospective study of HTLVI infection in an initially asymptomatic cohort. J Acquir Immune Defic Syndr. 1999;22: 92–100. doi: 10.1097/00042560-199909010-00012 10534152

23. Nagai M, Usuku K, Matsumoto W, Kodama D, Takenouchi N, Moritoyo T, et al. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: High proviral load strongly predisposes to HAM/TSP. J Neurovirol. 1998;4 (6): 586–593. doi: 10.3109/13550289809114225 10065900

24. Altamirano NA, Rocco C, Aulicino P, Sen L, Mangano A. Quantitation of HTLV-I proviral load by a real-time PCR assay using SYBR Green: Comparison of two methods for DNA isolation. J Virol Methods. 2010;170 (1–2): 160–164. doi: 10.1016/j.jviromet.2010.08.021 20816699

25. Ramezani S, Shirdel A, Rafatpanah H, Akbarin MM, Tarokhian H, Rahimi H, et al. Assessment of HTLV-1 proviral load, LAT, BIM, c-FOS and RAD51 gene expression in adult T cell leukemia/lymphoma. Med Microbiol Immunol. 2017;206 (4): 327–335. doi: 10.1007/s00430-017-0506-1 28466382

26. Furtado Mdos S1, Andrade RG, Romanelli LC, Ribeiro MA, Ribas JG, Torres EB, Barbosa-Stancioli EF, Proietti AB MM. Monitoring the HTLV-1 proviral load in the peripheral blood of asymptomatic carriers and patients with HTLV-associated myelopathy/tropical spastic paraparesis from a Brazilian cohort: ROC curve analysis to establish the threshold for risk disease. J Med Virol. 2012;84(4): 664–671. doi: 10.1002/jmv.23227 22337307

27. Kwaan N, Lee T-H, Chafets DM, Nass C, Newman B, Smith J, et al. Long-Term Variations in Human T Lymphotropic Virus (HTLV)–I and HTLV-II Proviral Loads and Association with Clinical Data. J Infect Dis. 2006;194: 1557–1564. doi: 10.1086/508899 17083040

28. Murphy EL, Lee T-H, Chafets D, Nass CC, Wang B, Loughlin K, et al. Higher human T lymphotropic virus (HTLV) provirus load is associated with HTLV-I versus HTLV-II, with HTLV-II subtype A versus B, and with male sex and a history of blood transfusion. J Infect Dis. 2004;190 (3): 504–510. doi: 10.1086/422398 15243924

29. Furukawa Y, Kubota R, Eiraku N, Nakagawa M, Usuku K, Izumo S OM. Human T-cell lymphotropic virus type I (HTLV-I)-related clinical and laboratory findings for HTLV-I-infected blood donors. J Acquir Immune Defic Syndr. 2003;32 (3): 328–334. doi: 10.1097/00126334-200303010-00013 12626894

30. Miller WC, Powers KA, Smith MK, Myron S, Hill C, Hill C, et al. Community viral load as a measure for assessment of HIV treatment as prevention. Lancet Infect Dis. 2013;13: 459–464. doi: 10.1016/S1473-3099(12)70314-6 Community 23537801

31. Castel AD, Befus M, Willis S, Griffin A, West T, Hader S, et al. Use of the community viral load as a population-based biomarker of HIV burden. Aids. 2012;26: 345–353. doi: 10.1097/QAD.0b013e32834de5fe 22008660

32. Hino S. Establishment of the milk-borne transmission as a key factor for the peculiar endemicity of human T-lymphotropic virus type 1 (HTLV-1): The ATL prevention program nagasaki. Proc Japan Acad Ser B Phys Biol Sci. 2011;87: 152–166. doi: 10.2183/pjab.87.152 21558754

33. Wiktor SZ1, Pate EJ, Rosenberg PS, Barnett M, Palmer P, Medeiros D, Maloney EM BW. Mother-to-child transmission of human T-cell lymphotropic virus type I associated with prolonged breast-feeding. J Hum Virol. 1997;Nov-Dec;1(.

34. Ishak R, Harrington WJ, Azevedo VN, Eiraku N, Ishak MOG, Guerreiro JF, et al. Identification of human T cell lymphotropic virus type IIa infection in the Kayapo, an indigenous population of Brazil. AIDS Res Hum Retroviruses. 1995;11: 813–821. doi: 10.1089/aid.1995.11.813 7546908

35. Stuver SO, Taehibana N, Okayama A, Shioiri S, Tsunetoshi Y, Tsuda K, et al. Heterosexual transmission of human t cell leukemia/lymphoma virus type i among married couples in southwestern Japan: An initial report from the miyazaki cohort study. J Infect Dis. 1993;167: 57–65. doi: 10.1093/infdis/167.1.57 8418183


Článek vyšel v časopise

PLOS One


2019 Číslo 11